National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee.
Standard
National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee. / Bishop, Michael R; Alyea, Edwin P; Cairo, Mitchell S; Falkenburg, J H Frederik; June, Carl H; Kröger, Nicolaus; Little, Richard F; Miller, Jeffrey S; Pavletic, Steven Z; Porter, David L; Riddell, Stanley R; van Besien, Koen; Wayne, Alan S; Weisdorf, Daniel J; Wu, Roy S; Giralt, Sergio.
In: BIOL BLOOD MARROW TR, Vol. 17, No. 4, 4, 2011, p. 443-454.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee.
AU - Bishop, Michael R
AU - Alyea, Edwin P
AU - Cairo, Mitchell S
AU - Falkenburg, J H Frederik
AU - June, Carl H
AU - Kröger, Nicolaus
AU - Little, Richard F
AU - Miller, Jeffrey S
AU - Pavletic, Steven Z
AU - Porter, David L
AU - Riddell, Stanley R
AU - van Besien, Koen
AU - Wayne, Alan S
AU - Weisdorf, Daniel J
AU - Wu, Roy S
AU - Giralt, Sergio
PY - 2011
Y1 - 2011
N2 - The National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation was organized and convened to identify, prioritize, and coordinate future research activities related to relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Each of the Workshop's 6 Working Committees has published individual reports of ongoing basic, translational, and clinical research and recommended areas for future research related to the areas of relapse biology, epidemiology, prevention, and treatment. This document summarizes each committee's recommendations and suggests 3 major initiatives for a coordinated research effort to address the problem of relapse after allo-HSCT: (1) to establish multicenter correlative and clinical trial networks for basic/translational, epidemiologic, and clinical research; (2) to establish a network of biorepositories for the collection of samples before and after allo-HSCT to aid in laboratory and clinical studies; and (3) to further refine, implement, and study the Workshop-proposed definitions for disease-specific response and relapse and recommendations for monitoring of minimal residual disease. These recommendations, in coordination with ongoing research initiatives and transplantation organizations, provide a research framework to rapidly and efficiently address the significant problem of relapse after allo-HSCT.
AB - The National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation was organized and convened to identify, prioritize, and coordinate future research activities related to relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Each of the Workshop's 6 Working Committees has published individual reports of ongoing basic, translational, and clinical research and recommended areas for future research related to the areas of relapse biology, epidemiology, prevention, and treatment. This document summarizes each committee's recommendations and suggests 3 major initiatives for a coordinated research effort to address the problem of relapse after allo-HSCT: (1) to establish multicenter correlative and clinical trial networks for basic/translational, epidemiologic, and clinical research; (2) to establish a network of biorepositories for the collection of samples before and after allo-HSCT to aid in laboratory and clinical studies; and (3) to further refine, implement, and study the Workshop-proposed definitions for disease-specific response and relapse and recommendations for monitoring of minimal residual disease. These recommendations, in coordination with ongoing research initiatives and transplantation organizations, provide a research framework to rapidly and efficiently address the significant problem of relapse after allo-HSCT.
KW - Humans
KW - Practice Guidelines as Topic
KW - Multicenter Studies as Topic
KW - Clinical Trials as Topic
KW - United States
KW - Recurrence
KW - Transplantation, Homologous
KW - Hematopoietic Stem Cell Transplantation
KW - Monitoring, Physiologic/methods
KW - Neoplasm, Residual
KW - Education
KW - Hematologic Neoplasms/prevention & control
KW - National Cancer Institute (U.S.)
KW - Humans
KW - Practice Guidelines as Topic
KW - Multicenter Studies as Topic
KW - Clinical Trials as Topic
KW - United States
KW - Recurrence
KW - Transplantation, Homologous
KW - Hematopoietic Stem Cell Transplantation
KW - Monitoring, Physiologic/methods
KW - Neoplasm, Residual
KW - Education
KW - Hematologic Neoplasms/prevention & control
KW - National Cancer Institute (U.S.)
M3 - SCORING: Journal article
VL - 17
SP - 443
EP - 454
JO - BIOL BLOOD MARROW TR
JF - BIOL BLOOD MARROW TR
SN - 1083-8791
IS - 4
M1 - 4
ER -
